In Debiopharm’s commitment to develop solutions to fight the COVID-19 pandemic, we are thrilled to announce that our portfolio company, Immunexpress Inc. has received CE Marking of SeptiCyte® RAPID, a one-hour molecular diagnostic test running on the Biocartis Idylla platform that can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients. Recent research from China identifies sepsis as the most frequently observed complication of COVID-19 patients. The immediate EU commercialization in partnership with Biocartis NV will support the use of the technology to improve the efficiency COVID-19 patient triage, quickly helping to identify patients with worsening prognoses and ensuring rapid initiation of sepsis management protocols that can increase the potential to save lives.
